VTP-300
Chronic Hepatitis B
Phase 1b/2aActive
Key Facts
About Barinthus Biotherapeutics
Barinthus Biotherapeutics is a UK-based, NASDAQ-listed biotech (BRNS) focused on developing novel immunotherapies for immunology and inflammatory (I&I) indications. The company's strategy centers on its two core technology platforms—the proprietary SNAP nanoparticle system and the established ChAdOx/MVA viral vectors—to 'guide' antigen-specific T cell responses. Recent clinical achievements include positive Phase 1b/2a data for its chronic hepatitis B candidate, VTP-300, showing sustained antigen reduction, and a favorable tolerability profile for its HPV candidate, VTP-200. Barinthus aims to translate its strong academic heritage into differentiated clinical assets in areas of high unmet need.
View full company profileTherapeutic Areas
Other Chronic Hepatitis B Drugs
| Drug | Company | Phase |
|---|---|---|
| ZM-H1505R | Zhimeng Biopharma | Phase 1 |
| Undisclosed CAM | Zhimeng Biopharma | Clinical |
| Undisclosed Immunomodulator | Zhimeng Biopharma | Clinical |
| Selgantolimod (GS-9688) | Gilead | Phase 2 |
| Bepirovirsen | GSK | Phase III |
| BRII-835 (VIR-2218) + BRII-179 (VBI-2601) | Brii Biosciences | Phase 2 |
| BRII-179 (VBI-2601) | Brii Biosciences | Phase 2a/2b |
| VIR-3434 | Brii Biosciences | Preclinical/Phase 1 (ex-China) |
| Collaboration with Aligos Therapeutics | Amoytop Biotech | Clinical |
| JNJ-3989 | Johnson & Johnson | Phase 2 |
| APG-1387 | Ascentage Pharma Group | Phase 2 |